Free Trial

Soleno Therapeutics Q4 2022 Earnings Report

Soleno Therapeutics logo
$46.88 +0.89 (+1.94%)
As of 01/17/2025 04:00 PM Eastern

Soleno Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.76
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Soleno Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Soleno Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Soleno Therapeutics Earnings Headlines

More AI patents than Nvidia, OpenAI and Tesla combined
If you own a smartphone, there’s a good chance you’re already benefiting from its technology—because it’s on hundreds of millions of devices worldwide. But you don’t see it’s logo on the outside of the tech gadgets you buy… That’s because it’s on the inside, making up the app’s and components that run your smartphone, your computer, and everything else…
See More Soleno Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soleno Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soleno Therapeutics and other key companies, straight to your email.

About Soleno Therapeutics

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

View Soleno Therapeutics Profile

More Earnings Resources from MarketBeat